Option grant gives enGene (NASDAQ: ENGN) CSO 195,000 shares

Rhea-AI Filing Summary

enGene Holdings Inc. reported a new equity award to its Chief Scientific Officer, Anthony Tzeyew Cheung. On January 30, 2026, he received a stock option to buy 195,000 common shares at an exercise price of $9.53 per share.

The option vests monthly in substantially equal amounts over 48 months, conditioned on his continued service. After this grant, he beneficially owns 195,000 derivative securities directly, aligning his compensation more closely with the company’s future share performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CHEUNG ANTHONY TZEYEW

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	195,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 195,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHEUNG ANTHONY TZEYEW

(Last) (First) (Middle)

C/O 4868 RUE LEVY, SUITE 220

(Street)

SAINT-LAURENT A8 H4R 2P1

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
enGene Holdings Inc. [ ENGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.53	01/30/2026		A		195,000		(1)	01/30/2036	Common Shares	195,000	$0	195,000	D

Explanation of Responses:

1. This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service.

	/s/ Anthony T. Cheung	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does enGene (ENGN) disclose in this latest Form 4 filing?

enGene reports a stock option grant to its Chief Scientific Officer. On January 30, 2026, Anthony Tzeyew Cheung received options for 195,000 common shares at a $9.53 exercise price, vesting monthly over 48 months, contingent on continued service.

How many enGene (ENGN) shares are covered by the new stock option?

The new stock option covers 195,000 common shares of enGene. These are derivative securities that allow the Chief Scientific Officer to buy shares at $9.53 per share, subject to a 48‑month monthly vesting schedule tied to ongoing employment.

What is the exercise price of the stock options granted by enGene (ENGN)?

The exercise price of the granted stock options is $9.53 per share. This means the Chief Scientific Officer can purchase up to 195,000 enGene common shares at $9.53, as the options vest monthly over 48 months, assuming continued service.

How do the enGene (ENGN) stock options granted to the CSO vest?

The stock options vest monthly over a 48‑month period. Vesting occurs in substantially equal monthly installments, and each installment depends on the Chief Scientific Officer’s continued service with enGene, gradually increasing his exercisable portion of the 195,000‑share grant.

What is the Chief Scientific Officer’s beneficial ownership after this enGene (ENGN) option grant?

After the grant, the officer beneficially owns 195,000 derivative securities. All 195,000 represent stock options held directly, giving him the right to acquire enGene common shares at $9.53 as the options vest over four years.

Is the enGene (ENGN) stock option grant to the CSO a cash transaction?

The grant itself is not a cash purchase; options were awarded at $0 cost. The exercise price is $9.53 per share, which would be paid only if and when the Chief Scientific Officer chooses to exercise vested options in the future.